Jennifer Y Lee1, Christopher J Danford2, Hirsh D Trivedi2, Elliot B Tapper3, Vilas R Patwardhan4, Alan Bonder5. 1. Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Ave., Boston, MA, 02215, USA. 2. Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, 330 Brookline Ave., Dana 603, Boston, MA, 02215, USA. 3. Division of Gastroenterology and Hepatology, University Hospital, University of Michigan, Floor 2, Room 2B353, 1500 E. Medical Center Dr SPC 5051, Ann Arbor, MI, 48109-5051, USA. 4. Liver Center, Autoimmune and Cholestatic Liver Disease Program, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA. 5. Liver Center, Autoimmune and Cholestatic Liver Disease Program, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA. abonder@bidmc.harvard.edu.
Abstract
BACKGROUND AND AIMS: Fatigue is the most common complication of primary biliary cholangitis (PBC) and can be debilitating. Numerous interventions have been trialed targeting several proposed mechanisms of PBC-associated fatigue. We sought to summarize and perform a meta-analysis to determine the efficacy of these interventions. METHODS: A comprehensive database search was conducted from inception through March 27, 2018. The primary outcome was proportion of fatigued patients or reduction in degree of fatigue. Adverse events were a secondary outcome. We assessed studies for risk of bias, graded quality of evidence, and used meta-analysis to obtain overall effect by pooling studies of the same class. RESULTS: We identified 16 studies evaluating ursodeoxycholic acid (UDCA) (7), liver transplantation (2), serotonin reuptake inhibitors (2), colchicine (1), methotrexate (1), cyclosporine (1), modafinil (1), and obeticholic acid (1). On meta-analysis, UDCA was not associated with a reduction in risk of fatigue (RR = 0.86, 95% CI 0.69-1.08, p = 0.19, I2 = 56.2%). While liver transplantation did reduce degree of fatigue (SMD - 0.57, 95% CI - 0.89 to - 0.24, p = 0.001, I2 = 67.3%), fatigue did not return to baseline indicating the underlying cause may not be addressed. CONCLUSIONS: While there is some improvement in fatigue with liver transplantation, there is a lack of high-quality evidence supporting the efficacy of any other intervention in the treatment of PBC-related fatigue. Further research into the underlying pathophysiology may help guide future trials.
BACKGROUND AND AIMS: Fatigue is the most common complication of primary biliary cholangitis (PBC) and can be debilitating. Numerous interventions have been trialed targeting several proposed mechanisms of PBC-associated fatigue. We sought to summarize and perform a meta-analysis to determine the efficacy of these interventions. METHODS: A comprehensive database search was conducted from inception through March 27, 2018. The primary outcome was proportion of fatiguedpatients or reduction in degree of fatigue. Adverse events were a secondary outcome. We assessed studies for risk of bias, graded quality of evidence, and used meta-analysis to obtain overall effect by pooling studies of the same class. RESULTS: We identified 16 studies evaluating ursodeoxycholic acid (UDCA) (7), liver transplantation (2), serotonin reuptake inhibitors (2), colchicine (1), methotrexate (1), cyclosporine (1), modafinil (1), and obeticholic acid (1). On meta-analysis, UDCA was not associated with a reduction in risk of fatigue (RR = 0.86, 95% CI 0.69-1.08, p = 0.19, I2 = 56.2%). While liver transplantation did reduce degree of fatigue (SMD - 0.57, 95% CI - 0.89 to - 0.24, p = 0.001, I2 = 67.3%), fatigue did not return to baseline indicating the underlying cause may not be addressed. CONCLUSIONS: While there is some improvement in fatigue with liver transplantation, there is a lack of high-quality evidence supporting the efficacy of any other intervention in the treatment of PBC-related fatigue. Further research into the underlying pathophysiology may help guide future trials.
Authors: Jayant A Talwalkar; Jessica J Donlinger; Andrea A Gossard; Jill C Keach; Roberta A Jorgensen; Janice C Petz; Keith D Lindor Journal: Dig Dis Sci Date: 2006-10-20 Impact factor: 3.199
Authors: Carmen M Stanca; Nancy Bach; Cynthia Krause; Nidhi Tandon; Maria A Freni; Julio A Gutierrez; Carol Bodian; Jose Lopez; Paul D Berk; Henry C Bodenheimer; Andrea D Branch; Joseph A Odin Journal: Am J Gastroenterol Date: 2005-05 Impact factor: 10.864
Authors: C W Chan; F Gunsar; M Feudjo; C Rigamonti; J Vlachogiannakos; J R Carpenter; A K Burroughs Journal: Aliment Pharmacol Ther Date: 2005-02-01 Impact factor: 8.171
Authors: E J Heathcote; K Cauch-Dudek; V Walker; R J Bailey; L M Blendis; C N Ghent; P Michieletti; G Y Minuk; S C Pappas; L J Scully Journal: Hepatology Date: 1994-05 Impact factor: 17.425
Authors: Vinod S Hegade; Stuart F W Kendrick; Robert L Dobbins; Sam R Miller; Douglas Thompson; Duncan Richards; James Storey; George E Dukes; Margaret Corrigan; Ronald P J Oude Elferink; Ulrich Beuers; Gideon M Hirschfield; David E Jones Journal: Lancet Date: 2017-02-08 Impact factor: 79.321
Authors: Greta Pells; George F Mells; Marco Carbone; Julia L Newton; Andrew J Bathgate; Andrew K Burroughs; Michael A Heneghan; James M Neuberger; Darren B Day; Samantha J Ducker; Richard N Sandford; Graeme J Alexander; David E J Jones Journal: J Hepatol Date: 2013-03-04 Impact factor: 25.083
Authors: Lucas H P Bernts; David E J Jones; Marleen M Kaatee; Ansgar W Lohse; Christoph Schramm; Ekkehard Sturm; Joost P H Drenth Journal: Orphanet J Rare Dis Date: 2019-07-08 Impact factor: 4.123